Chronic amphetamine treatment reduces NGF and BDNF in the rat brain

European Neuropsychopharmacology

Volumn 17, Issue 12, 2007, Pages 756-762

  Angelucci, Francesco ^a,b   Gruber, Susanne H M ^a   El Khoury, Aram ^a   Tonali, Pietro Attilio ^b   Mathé, Aleksander A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Amphetamine; BDNF; NGF; Rat brain; Schizophrenia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE RECEPTOR STIMULATING AGENT; METHAMPHETAMINE; NERVE GROWTH FACTOR; NEUROTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; HYPOTHALAMUS; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OCCIPITAL CORTEX; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM STIMULANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; MALE; NERVE GROWTH FACTOR; RATS; RATS, WISTAR; TIME FACTORS;

EID: 35348859432     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.03.002     Document Type: Article

References (58)

1. Angelucci F., Aloe L., Jimenez-Vasquez P., and Mathe A.A. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int. J. Neuropsychopharmacol. 6 (2003) 225-231
2. Angelucci F., Mathé A.A., and Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog. Brain Res. 146 (2004) 151-165
3. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., and Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 15 (2005) 311-317
4. Angelucci F., Brene S., and Mathé A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 10 (2005) 345-352
5. Antonova E., Kumari V., Morris R., Halari R., Anilkumar A., Mehrotra R., and Sharma T. The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol. Psychiatry 58 (2005) 457-467
6. Balse E., Suhr R., Haaf A., Kelche C., Jackisch R., and Cassel J.C. The potentiation of amphetamine-induced hyperlocomotion by fimbria-fornix lesions in rats is abolished by intrahippocampal grafts rich in serotonergic neurons. Neurosci. Lett. 265 (1999) 79-82
7. Bariohay B., Lebrun B., Moyse E., and Jean A. Brain-derived neurotrophic factor plays a role as an anorexigenic factor in the dorsal vagal complex. Endocrinology 146 (2005) 5612-5620
8. Barkataki I., Kumari V., Das M., Taylor P., and Sharma T. Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder. Behav. Brain Res. 169 (2006) 239-247
9. Bersani G., Iannitelli A., Maselli P., Pancheri P., Aloe L., Angelucci F., and Alleva E. Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophr. Res. 37 (1999) 201-203
10. Blum R., and Konnerth A. Neurotrophin-mediated rapid signaling in the central nervous system: mechanisms and functions. Physiology 20 (2005) 70-78
11. Conner J.M., Lauterborn J.C., and Gall C.M. Anterograde transport of neurotrophin proteins in the CNS-a reassessment of the neurotrophic hypothesis. Rev. Neurosci. 9 (1998) 91-103
12. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., Santin A., and Kapczinski F. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398 (2006) 215-219
13. Dalmau A., Bergman B., and Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness?. Eur. Psychiatr. 14 (1999) 366-371
14. Davidson C., Gow A.J., Lee T.H., and Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brain Res. Rev. 36 (2001) 1-22
15. Duman R.S. Synaptic plasticity and mood disorders. Mol. Psychiatry 7 (2002) S29-S34
16. Durany N., and Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur. Psychiatr. 19 (2004) 326-337
17. Einat H., Kofman O., and Belmaker R.H. Animal models of bipolar disorder: from a single episode to progressive cycling models. In: Myslobodsky M., and Weiner I. (Eds). Contemporary Issues in Modeling Psychopathology (2000), Kluwer Academic Publishers, Boston 165-180
18. Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res. Brain Res. Rev. 19 (1994) 223-239
19. Frey B.N., Andreazza A.C., Cereser K.M., Martins M.R., Valvassori S.S., Reus G.Z., Quevedo J., and Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. 79 (2006) 281-286
20. Frey B.N., Andreazza A.C., Rosa A.R., Martins M.R., Valvassori S.S., Reus G.Z., Hatch J.P., Quevedo J., and Kapczinski F. Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behav. Pharmacol. 17 (2006) 311-318
21. Fuji K., Hiramatsu M., Kameyama T., and Nabeshima T. Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats. Eur. J. Pharmacol. 236 (1993) 411-417
22. Gibb J.W., Hanson G.R., and Johnson M. Neurochemical mechanisms of toxicity. In: Cho A.K., and Segal D.S. (Eds). Amphetamine and Its Analogs (1994), Academic Press, CA 269-295
23. Glowinski J., and Iversen L.L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem. 13 (1966) 655-669
24. Gruber S.H., Nomikos G.G., and Mathé A.A. Dopamine receptor antagonists prevent the d-amphetamine-induced increase in calcitonin gene-related peptide levels in ventral striatum. J. Neurosci. Res. 64 (2001) 606-611
25. Hashimoto K., Koizumi H., Nakazato M., Shimizu E., and Iyo M. Role of brain-derived neurotrophic factor in eating disorders: recent findings and its pathophysiological implications. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 499-504
26. Hertel P., Mathé J.M., Nomikos G.G., Iurlo M., Mathé A.A., and Svensson T.H. Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 72 (1995) 103-114
27. Hsieh Y.S., Yang S.F., and Kuo D.Y. Amphetamine, an appetite suppressant, decreases neuropeptide Y immunoreactivity in rat hypothalamic paraventriculum. Regul. Pept. 127 (2005) 169-176
28. Iritani S., Niizato K., Nawa H., Ikeda K., and Emson P.C. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 801-807
29. Jockers-Scherubl M.C., Danker-Hopfe H., Mahlberg R., Selig F., Rentzsch J., Schurer F., Lang U.E., and Hellweg R. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci. Lett. 371 (2004) 79-83
30. Karler R., Calder L.D., Thai L.H., and Bedingfield J.B. The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine. Brain Res. 671 (1995) 100-104
31. Knable M.B., and Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11 (1997) 123-131
32. Kim D.J., Roh S., Kim Y., Yoon S.J., Lee H.K., Han C.S., and Kim Y.K. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci. Lett. 388 (2005) 112-115
33. Machado-Vieira R., Kapczinski F., and Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 209-224
34. Mandillo S., Rinaldi A., Oliverio A., and Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav. Pharmacol. 14 (2003) 533-544
35. Mathé A.A., Hertel P., Nomikos G.G., Gruber S., Mathé J.M., and Svensson T.H. The psychotomimetic drugs d-amphetamine and phencyclidine release calcitonin gene-related peptide in the limbic forebrain of the rat. J. Neurosci. Res. 46 (1996) 316-323
36. Matsuzaki H., Namikawa K., Kiyama H., Mori N., and Sato K. Brain-derived neurotrophic factor rescues neuronal death induced by methamphetamine. Biol. Psychiatry 55 (2004) 52-60
37. Mattsson A., Ogren S.O., and Olson L. Facilitation of dopamine-mediated locomotor activity in adult rats following cholinergic denervation. Exp. Neurol. 174 (2002) 96-108
38. McCann U.D., and Ricaurte G.A. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci. Biobehav. Rev. 27 (2004) 821-826
39. Meredith G.E., Callen S., and Scheuer D.A. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res. 949 (2002) 218-227
40. Naert G., Ixart G., Tapia-Arancibia L., and Givalois L. Continuous i.c.v. infusion of brain-derived neurotrophic factor modifies hypothalamic-pituitary-adrenal axis activity, locomotor activity and body temperature rhythms in adult male rats. Neuroscience 139 (2006) 779-789
41. Pereira P.A., Cardoso A., and Paula-Barbosa M.M. Nerve growth factor restores the expression of vasopressin and vasoactive intestinal polypeptide in the suprachiasmatic nucleus of aged rats. Brain Res. 1048 (2005) 123-130
42. Pirildar S., Gonul A.S., Taneli F., and Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 709-713
43. Ricaurte G.A., Mechan A.O., Yuan J., Hatzidimitriou G., Xie T., Mayne A.H., and McCann U.D. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J. Pharmacol. Exp. Ther. 315 (2005) 91-98
44. Rung J.P., Carlsson A., Ryden Markinhuhta K., and Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 827-832
45. Scaccianoce S., Lombardo K., Nicolai R., Affricano D., and Angelucci L. Studies on the involvement of histamine in the hypothalamic-pituitary-adrenal axis activation induced by nerve growth factor. Life Sci. 67 (2000) 3143-3152
46. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., and Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci. Lett. 351 (2003) 111-114
47. Shoval G., and Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 15 (2005) 319-329
48. Sigmundsson T., Suckling J., Maier M., Williams S., Bullmore E., Greenwood K., Fukuda R., Ron M., and Toone B. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am. J. Psychiatry 158 (2001) 234-243
49. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., and Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738 (1996) 172-175
50. Tabakman R., Lecht S., Sephanova S., Arien-Zakay H., and Lazarovici P. Interactions between the cells of the immune and nervous system: neurotrophins as neuroprotection mediators in CNS injury. Prog. Brain Res. 146 (2004) 387-401
51. Tamminga C.A., and Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 10 (2005) 27-39
52. Tan Y.L., Zhou D.F., and Zhang X.Y. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 74 (2005) 263-270
53. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., Lee J.Y., Toga A.W., Ling W., and London E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J. Neurosci. 24 (2004) 6028-6036
54. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., and Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 110 (2002) 249-257
55. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., and Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 8 (2003) 592-610
56. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., Weinberger D.R., and Kleinman J.E. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 10 (2005) 637-650
57. Weinberger D.R., and Lipska B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr. Res. 16 (1995) 87-110
58. Yamasue H., Iwanami A., Hirayasu Y., Yamada H., Abe O., Kuroki N., Fukuda R., Tsujii K., Aoki S., Ohtomo K., Kato N., and Kasai K. Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiatry Res. 131 (2004) 195-207